The following statistical data will be obtained: 
A) time to reconstitution 
neutrophils >500 
platelets >50,000 (untransfused) 
B) survival 
C) disease-free survival 
D) disease recurrence 
rate 
length of remission 
E) adverse reactions 
secondary malignancy 
replication-competent murine retrovirus 
unexpected 
The patient population selected is expected to have a 
high rate of disease recurrence with disease-free 
survival estimated at less than 20%. Toxicities 
secondary to transplant is expected in 100% of patients 
but the treatment-related mortality is estimated to be 
approximately 10%. Only side effects from the RMGT will 
be evaluated and reported as adverse reactions for this 
study . 
For evaluation of relapsed patients meaningful data will 
only be obtained in patients who show evidence of the 
neo* gene in blast cells. If blast cells do not show 
evidence of the marker gene, it is unlikely that 
significant data can be generated because the number of 
leukemic cells in the transfused marrow, the infection of 
the cell(s) which lead to disease recurrence, the extent 
of residual leukemia in the patient after the bone marrow 
transplant preparative regimen and the effectiveness of 
the host immune system on eradicating residual leukemia 
are unknown. 
9.0 PATHOLOGY REVIEW: 
Pathology material required for enrollment include the 
original bone marrow specimen at the time of diagnosis or 
relapse, a complete remission marrow within three weeks 
[496] 
Recombinant DNA Research, Volume 15 
